- Home
- BSM vs MLTX Comparison
BSM vs MLTX Comparison
Compare BSM & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSM
- MLTX
- Stock Information
- Founded
- BSM 1876
- MLTX 2021
- Country
- BSM United States
- MLTX Switzerland
- Employees
- BSM N/A
- MLTX N/A
- Industry
- BSM Oil & Gas Production
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- BSM Energy
- MLTX Health Care
- Exchange
- BSM Nasdaq
- MLTX Nasdaq
- Market Cap
- BSM 3.1B
- MLTX 2.8B
- IPO Year
- BSM 2015
- MLTX N/A
- Fundamental
- Price
- BSM $13.09
- MLTX $47.86
- Analyst Decision
- BSM Hold
- MLTX Strong Buy
- Analyst Count
- BSM 1
- MLTX 7
- Target Price
- BSM $14.00
- MLTX $73.33
- AVG Volume (30 Days)
- BSM 466.4K
- MLTX 757.5K
- Earning Date
- BSM 08-04-2025
- MLTX 08-06-2025
- Dividend Yield
- BSM 11.44%
- MLTX N/A
- EPS Growth
- BSM N/A
- MLTX N/A
- EPS
- BSM 0.92
- MLTX N/A
- Revenue
- BSM $422,061,000.00
- MLTX N/A
- Revenue This Year
- BSM $12.38
- MLTX $103.42
- Revenue Next Year
- BSM $11.17
- MLTX N/A
- P/E Ratio
- BSM $14.26
- MLTX N/A
- Revenue Growth
- BSM N/A
- MLTX N/A
- 52 Week Low
- BSM $12.78
- MLTX $31.42
- 52 Week High
- BSM $16.03
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- BSM 40.61
- MLTX 63.33
- Support Level
- BSM $12.78
- MLTX $46.24
- Resistance Level
- BSM $13.34
- MLTX $48.72
- Average True Range (ATR)
- BSM 0.25
- MLTX 1.60
- MACD
- BSM -0.01
- MLTX 0.10
- Stochastic Oscillator
- BSM 24.41
- MLTX 86.77
About BSM Black Stone Minerals L.P. Common units representing limited partner interests
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.